Rezdiffra (resmetirom) is a brand-name drug prescribed for a type of liver disease called metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH) ...
Rezdiffra (resmetirom) is a brand-name oral tablet prescribed for nonalcoholic steatohepatitis (NASH) in certain situations. It is typically taken once per day. The dosage varies based on a person’s ...
The prescribed dosage for Rezdiffra (resmetirom) may depend on a person’s individual treatment plan. Factors like your medical history and body weight may affect your dosage of Rezdiffra. Rezdiffra ...
Please provide your email address to receive an email when new articles are posted on . Experts recommend confirming MASH diagnosis by assessing steatosis via ultrasound or FibroScan. MRI-proton ...
Rezdiffra (resmetirom) has potential interactions with other medications. These interactions could affect how well the drug works or cause harmful effects. Rezdiffra is used in adults to treat ...
CONSHOHOCKEN, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic ...
In its first full quarter on the market, Madrigal Pharmaceuticals’ Rezdiffra, the first treatment for metabolic dysfunction-associated steatohepatitis (MASH), achieved sales of $14.6 million. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results